drugset / Trial / NCT03994913
Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma
Phase 1/2
Completed
20 enrolled
CARsgen Therapeutics Co., Ltd.
First Affiliated Hospital of Zhejiang University · collabRenJi Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT032 CAR-CD19 T in patients with relapsed and/or refractory non-Hodgkin's B cell lymphoma (R/R B-NHL).
Timeline
- Start
- 2019-08-14
- Primary completion
- 2021-01-20
- Completion
- 2021-05-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-CD19 T cells | Cell therapy | — | — |